If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

β-Lactamase Inhibitors: The Story so Far

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

Antimicrobial resistance constitutes one of the major threats regarding pathogenic microorganisms. Gramnegative pathogens, such as Enterobacteriaceae (specially those producing extended-spectrum β-lactamases), Pseudomonas aeruginosa, and Acinetobacter baumannii, have acquired an important role in hospital infections, which is of particular concern because of the associated broad spectrum of antibiotic resistance.

β-Lactam antibiotics are considered the most successful antimicrobial agents since the beginning of the antibiotic era. Soon after the introduction of penicillin, microorganisms able to destroy this β-lactam antibiotic were reported, thus, emphasizing the facility of pathogenic microorganisms to develop β-lactam resistance. In Gram-negative pathogens, β- lactamase production is the main mechanism involved in acquired β-lactam resistance. Four classes of β-lactamases have been described: A, B, C, and D. Classes A, C, and D are enzymes with a serine moiety in the active centre that catalyzes hydrolysis of the β -lactam ring through an acyl-intermediate of serine, whereas the class B enzymes require a metal cofactor (e.g. zinc in the natural form) to function, and for this reason, they are also referred to as metallo- β-lactamases (MBLs).

To overcome β-lactamase-mediated resistance, a combination of β-lactam and a β-lactamase inhibitor, which protects the β-lactam antibiotic from the activity of the β-lactamase, has been widely used in the treatment of human infections. Although there are some very successful combinations of β-lactams and ??-lactamase inhibitors, most of the inhibitors act against class A β-lactamases and remain ineffective against class B, C, and D β-lactamases.

This review constitutes an update of the current status and knowledge regarding class A to D β-lactamase inhibitors, as well as a summary of the drug discovery strategy currently used to identify new ??-lactamase inhibitors, mainly based on the knowledge of crystal structure of β-lactamase enzymes.

Keywords: Antibiotic resistance; antimicrobial design; drug discovery

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986709789104957

Affiliations: Laboratorio de Microbiologia, CH Universitario A Coruna-INIBIC, Xubias de Arriba, s/n, 15006, A Coruna Spain.

Publication date: October 1, 2009

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more